Marshall Urist

CIK: 0001838139

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)18 (64.3%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)3 (10.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RPRX

Royalty Pharma plc

Officer

Discretionary Trading P&L

Holdings

Transaction History (28 total)

RPRX
Royalty Pharma plc
Oct 5, 2026
Sale(S)
Direct
4.1K shares at avg. $57.10$236K
RPRX
Royalty Pharma plc
Sep 28, 2026
Sale(S)
Direct
4.1K shares at avg. $57.88$239K
RPRX
Royalty Pharma plc
Aug 7, 2026
Gift(G)
LP interests in RPI US Partners 2019, LP
Indirect
3K shares-
RPRX
Royalty Pharma plc
Aug 5, 2026
Award(A)
Direct
8.3K shares-
RPRX
Royalty Pharma plc
Jul 1, 2026
Sale(S)
Direct
9.1K shares at avg. $55.88$508K
RPRX
Royalty Pharma plc
Jun 24, 2026
Sale(S)
Direct
9.1K shares at avg. $55.18$502K
RPRX
Royalty Pharma plc
May 20, 2026
Sale(S)
Direct
13.7K shares at avg. $52.75$722K
RPRX
Royalty Pharma plc
May 14, 2026
Sale(S)
Direct
13.7K shares at avg. $53.06$726K
RPRX
Royalty Pharma plc
May 6, 2026
Award(A)
Direct
18.2K shares-
RPRX
Royalty Pharma plc
Feb 11, 2026
Award(A)
Direct
20K shares-
RPRX
Royalty Pharma plc
Jan 30, 2026
Sale(S)
Indirect
20K shares at avg. $41.09$822K
RPRX
Royalty Pharma plc
Jan 23, 2026
Sale(S)
Indirect
20K shares at avg. $40.26$805K
RPRX
Royalty Pharma plc
Jan 16, 2026
Sale(S)
Indirect
20K shares at avg. $39.52$790K
RPRX
Royalty Pharma plc
Jan 9, 2026
Sale(S)
Indirect
20K shares at avg. $40.78$816K
RPRX
Royalty Pharma plc
Jan 2, 2026
Sale(S)
Indirect
20K shares at avg. $38.48$770K
RPRX
Royalty Pharma plc
Dec 26, 2025
Sale(S)
Indirect
20K shares at avg. $39.32$786K
RPRX
Royalty Pharma plc
Dec 19, 2025
Sale(S)
Indirect
20K shares at avg. $38.38$768K
RPRX
Royalty Pharma plc
Dec 16, 2025
Sale(S)
Indirect
20K shares at avg. $38.32$766K
RPRX
Royalty Pharma plc
Dec 5, 2025
Sale(S)
Direct
18.2K shares at avg. $39.15$714K
RPRX
Royalty Pharma plc
Dec 5, 2025
Sale(S)
Indirect
23.3K shares at avg. $39.15$914K
RPRX
Royalty Pharma plc
Dec 1, 2025
Sale(S)
Indirect
23.3K shares at avg. $39.93$932K
RPRX
Royalty Pharma plc
Dec 1, 2025
Sale(S)
Direct
18.2K shares at avg. $39.90$728K
RPRX
Royalty Pharma plc
Nov 7, 2025
Conversion(C)
Indirect
160K shares-
RPRX
Royalty Pharma plc
Nov 5, 2025
Award(A)
Direct
4.6K shares-
RPRX
Royalty Pharma plc
Aug 8, 2025
Gift(G)
LP interests in RPI US Partners 2019, LP
Indirect
3K shares-

		Type	Shares	Price		Ownership
Oct 5, 2026	RPRX Royalty Pharma plc	Sale(S)	4,126	$57.10	$235,595	Direct
Sep 28, 2026	RPRX Royalty Pharma plc	Sale(S)	4,126	$57.88	$238,813	Direct
Aug 7, 2026	RPRX Royalty Pharma plc	Gift(G) LP interests in RPI US Partners 2019, LP	3,000	-	-	Indirect
Aug 5, 2026	RPRX Royalty Pharma plc	Award(A)	8,252	-	$0	Direct
Jul 1, 2026	RPRX Royalty Pharma plc	Sale(S)	9,099	$55.88	$508,454	Direct
Jun 24, 2026	RPRX Royalty Pharma plc	Sale(S)	9,098	$55.18	$502,067	Direct
May 20, 2026	RPRX Royalty Pharma plc	Sale(S)	13,684	$52.75	$721,838	Direct
May 14, 2026	RPRX Royalty Pharma plc	Sale(S)	13,684	$53.06	$726,137	Direct
May 6, 2026	RPRX Royalty Pharma plc	Award(A)	18,197	-	$0	Direct
Feb 11, 2026	RPRX Royalty Pharma plc	Award(A)	19,970	-	$0	Direct
Jan 30, 2026	RPRX Royalty Pharma plc	Sale(S)	20,000	$41.09	$821,810	Indirect
Jan 23, 2026	RPRX Royalty Pharma plc	Sale(S)	20,000	$40.26	$805,110	Indirect
Jan 16, 2026	RPRX Royalty Pharma plc	Sale(S)	20,000	$39.52	$790,346	Indirect
Jan 9, 2026	RPRX Royalty Pharma plc	Sale(S)	20,000	$40.78	$815,634	Indirect
Jan 2, 2026	RPRX Royalty Pharma plc	Sale(S)	20,000	$38.48	$769,650	Indirect
Dec 26, 2025	RPRX Royalty Pharma plc	Sale(S)	20,000	$39.32	$786,380	Indirect
Dec 19, 2025	RPRX Royalty Pharma plc	Sale(S)	20,000	$38.38	$767,582	Indirect
Dec 16, 2025	RPRX Royalty Pharma plc	Sale(S)	20,000	$38.32	$766,420	Indirect
Dec 5, 2025	RPRX Royalty Pharma plc	Sale(S)	18,242	$39.15	$714,224	Direct
Dec 5, 2025	RPRX Royalty Pharma plc	Sale(S)	23,334	$39.15	$913,591	Indirect
Dec 1, 2025	RPRX Royalty Pharma plc	Sale(S)	23,333	$39.93	$931,633	Indirect
Dec 1, 2025	RPRX Royalty Pharma plc	Sale(S)	18,242	$39.90	$727,856	Direct
Nov 7, 2025	RPRX Royalty Pharma plc	Conversion(C)	160,000	-	-	Indirect
Nov 5, 2025	RPRX Royalty Pharma plc	Award(A)	4,626	-	-	Direct
Aug 8, 2025	RPRX Royalty Pharma plc	Gift(G) LP interests in RPI US Partners 2019, LP	3,000	-	-	Indirect

1-25 of 28 transactions

About Urist Marshall

Urist Marshall (SEC CIK 0001838139) files insider reports with the SEC as EVP, Research & Investments of Royalty Pharma plc (RPRX).

Signal8 holds 23 ownership filings by Urist Marshall, all Form 4s, filed between May 9, 2025 and Oct 5, 2026. Those filings report 28 transactions, from May 8, 2025 to Oct 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Urist Marshall's filings is in NEW YORK, NY.

Recent filings by Urist Marshall

Oct 5, 2026: Open-market sale of RPRX shares (Form 4, code S).
Sep 28, 2026: Open-market sale of RPRX shares (Form 4, code S).
Aug 7, 2026: Gift of RPRX derivative securities (Form 4, code G).
Aug 5, 2026: Grant or award of RPRX shares (Form 4, code A).
Jul 1, 2026: Open-market sale of RPRX shares (Form 4, code S).

Other insiders filing for Royalty Pharma plc (RPRX)

Bassler Bonnie L, Director
Hite Christopher, EVP & Chairman, Partnering
Coyne Terrance P., EVP & CFO
Legorreta Pablo G., CEO, Chairman of the Board
WEATHERMAN ELIZABETH H, Director
Norden Gregory, Director

How to read Form 4 transaction codes